The short answer
Davies and colleagues published a metabolic comparison of GIP receptor agonism against antagonism in male mice in Diabetes, Obesity and Metabolism in February 2026. The first time the two opposing strategies have been tested side by side in one model rather than inferred across separate human trials.
Key facts
- Direct comparison
- Davies 2026 (PMID 41287212)
- Model
- Male mice
- Agonism example
- Tirzepatide (with GLP-1 agonism)
- Antagonism example
- Maridebart cafraglutide
- Case for agonism
- Samms 2025 (PMID 40521890)
- Human question
- Still unresolved
Why the paradox exists at all
Tirzepatide activates the GIP receptor and produces substantial weight reduction. Maridebart cafraglutide blocks the same receptor and also produces substantial weight reduction. Both are paired with GLP-1 receptor agonism. Opposite manipulations of one target apparently producing the same directional outcome is the kind of result that indicates something in the model is wrong.
Why the existing evidence could not settle it
Every comparison until now was across trials. Different compounds, different formats, different doses, different populations, different durations. Cross-trial comparison cannot attribute a difference to the receptor when everything else differs too. That is the same structural problem that makes head-to-heads necessary in the clinical literature.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What a matched preclinical comparison adds
One species, one model, both directions, conditions held constant. Davies and colleagues compared the metabolic consequences of agonism and antagonism in male mice, which is the design that can actually isolate the variable. It is the right experiment for the question even though it is not in humans.
The candidate explanations it can discriminate between
Several have been proposed. That sustained agonism desensitises the receptor, making chronic agonism functionally equivalent to blockade. That the two act in different tissues (central versus adipose) with opposite roles. That GIP receptor manipulation in either direction mainly modulates tolerability of the GLP-1 component rather than driving weight loss itself. A matched comparison produces data these hypotheses predict differently.
The case for agonism, stated by its proponents
Samms and colleagues published a contemporary rationale for GIP receptor agonism in obesity in Diabetes in August 2025. Reading it alongside the antagonist clinical programme is the honest way to hold this question, two serious arguments, both with supporting data, and no resolution yet.
What a mouse study does not settle
The human question. Rodent metabolic physiology differs from human in ways that matter for incretin biology specifically, and compounds behave differently across species. This narrows the hypothesis space; it does not tell you which clinical strategy is better, and only a human head-to-head could.
Frequently asked questions
How can blocking and activating a receptor both cause weight loss?
That is the paradox. Proposed explanations include receptor desensitisation under chronic agonism, opposing roles in different tissues, and effects mainly on tolerability of the GLP-1 component.
What is new about the 2026 study?
It compared both directions in one model under matched conditions, rather than inferring across separate trials of separate compounds.
Does it resolve the question?
No. It is a mouse study, and rodent incretin physiology differs from human. It narrows the hypotheses rather than choosing between clinical strategies.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDavies I et al., A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice. Diabetes Obes Metab 2026 (PMID 41287212)pubmed.ncbi.nlm.nih.gov
- PubMedSamms RJ et al., A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity. Diabetes 2025 (PMID 40521890)pubmed.ncbi.nlm.nih.gov
- PubMedJastreboff AM et al., Once-Monthly Maridebart Cafraglutide. NEJM 2025 (PMID 40549887)pubmed.ncbi.nlm.nih.gov
- PubMedThe Paradox and Future of GLP-1/GIP Combination Therapies. Annu Rev Nutr 2026 (PMID 42166683)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Why Population-Specific Trials Are RunOASIS 2 studied oral semaglutide in an East Asian population. Why obesity thresholds and drug response differ, and what a dedicated trial establishes.
- The Question Underneath the Lean Mass DebateAll weight loss costs fat-free mass, including diet and surgery. The real questions are whether incretins cost more, and whether it has functional consequences.
- What Fat-Free Mass Actually ContainsBone, organs, water and blood-forming tissue all sit inside the fat-free compartment. Treating the number as a muscle measurement is a category error.
- The Method Determines the NumberDXA and bioimpedance do not agree, and they disagree most during active weight change. Why a lean mass percentage is partly a property of the instrument.
- Blocking the Brake on Muscle GrowthMyostatin restrains muscle growth through activin type II receptors. Blocking them preserves muscle - and a 2024 paper reports it enhances fat loss too.